The new pairing combines Tandem’s flagship automated insulin delivery system with Control-IQ+ technology with Abbott’s latest continuous glucose monitor (CGM) sensor in the U.S. Tandem teased the launch on social media earlier this month after the companies first agreed to integrate systems in June. At that point, Tandem already initiated an early access program for integration in the U.S. with plans to scale availability in the second half of 2025.

It marks the latest integration between the diabetes technology developers — two of the world’s largest — following the integration of FreeStyle Libre 2 Plus CGM into the t:slim X2 insulin pump in January 2024. Earlier this year, the companies announced the future pairing of Tandem systems with Abbott’s under-development dual glucose-ketone sensor.